How to Buy Sutro Biopharma Stock
Sutro Biopharma Inc
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company.
Sutro Biopharma stock last closed at $30.62, down 16.49% from the previous day, and has increased 183.29% in one year. It has overperformed other stocks in the Biotechnology industry by 2.59 percentage points. Sutro Biopharma stock is currently +354.57% from its 52-week low of $6.74, and -30.17% from its 52-week high of $43.85.
There are currently 16.57M STRO shares outstanding. The market capitalization of STRO is $507.39M. In the last 24 hours, 365,000 STRO shares were traded.
How to Buy Sutro Biopharma Stock
Not sure how to invest in Sutro Biopharma stock? Here's how.
- Figure out where to buy Sutro Biopharma stock: You need to choose a stock brokerage, but don't worry - we've tried dozens of online stock brokerages and apps to help you determine where to buy Sutro Biopharma stock.
- Create your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've selected.
- Put funds into your investment account: Choose your method of payment and add your info.
- Analyze Sutro Biopharma stock: The Sutro Biopharma ticker symbol is STRO. Is Sutro Biopharma stock a good investment? Should you buy shares of STRO? How do STRO's underlying business fundamentals look? Do top analysts think Sutro Biopharma is a good buy? Why has STRO's stock price moved recently? (Hint: Our stock market analysis tools can help you evaluate if STRO is a good stock to buy).
- Execute your STRO buy order: Decide if you will purchase STRO shares at the current market price or use a limit order to buy STRO stock at a specific price.
- Keep tabs on your STRO position: Create a watchlist to keep tabs on your position in Sutro Biopharma shares.
Step 1: Figure out where to buy Sutro Biopharma stock
You will need an online brokerage account in order to access the NASDAQ market and buy STRO shares.
Our favorite brokerage: eToro
In our opinion, eToro is the best place to buy stocks. Here's why:
- Invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still purchase the stock.
- Access to global markets: From Tech to Real Estate, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top stock exchanges.
- Social investing: eToro has a community with more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your share purchase by creating an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Create your brokerage account
Now that you've selected the best brokerage, the next step is to fill out some personal info so you are able to buy STRO stock today.
How to Create a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal data to start your new trading account.
- Submit your details by clicking the "Create Account" button. Get started with eToro today
Step 3: Put funds into your investment account
Now that you have created your account on the best investment app, you can securely and quickly fund your account:
Check out the video below if you need help transferring funds into your new investment account.
Step 4: Analyze Sutro Biopharma stock
After you have selected the best place to buy Sutro Biopharma stock, it's very important to research their stock prior to investing, so you can understand the risk and upside.
Sutro Biopharma Metrics
STRO Due Diligence Score
WallStreetZen was built to help average investors do better fundamental analysis in less time.
You can view all of the due diligence checks on STRO's stock page.
Is STRO stock undervalued or overvalued?
Analysts use many financial metrics, analyses, models, and charts to gauge STRO's fair value.
You can access additional valuation research on STRO's stock here.
A quick look at STRO Financials
Passed Health Checks:
- There are more short-term assets than short-term liabilities on the STRO balance sheet.
- STRO has cash burn of 152139000. It has sufficient cash and short-term investments to cover this for at least one year.
Failed Health Checks:
- STRO debt to equity ratio of -4.62 is negative.
- STRO profit margin has gone up by 2.15 percentage points in the past year, but the company is still unprofitable.
- Total STRO debt is still negative.
- STRO has $203.42M in cash and short term investments. This is not sufficient to cover its annual cash burn of $152.14M.
- There are more long-term liabilities than short-term assets on the STRO balance sheet.
Is it a good time to buy STRO stock, according to analysts?
Out of 7 Equities analysts who track STRO, the consensus analyst rating on Sutro Biopharma is a Strong Buy
It's important to keep in mind that analyst forecasts are not stock recommendations, nor are they investment advice.
Most Recent STRO Analyst Recommendations
James Shin, a top 28% analyst from Deutsche Bank maintains STRO with a strong buy rating and raises their STRO price target from $51.00 to $55.00, on Mar 25, 2026.
Eva Fortea Verdejo, a top 8% analyst from Wells Fargo upgrades STRO to a strong buy rating and raises their STRO price target from $8.00 to $27.00, on Mar 24, 2026.
Wells Fargo's Eva Fortea Verdejo upgraded their rating on Sutro Biopharma (NASDAQ: STRO) from Hold to Strong Buy on 2026/03/24. The analyst also raised their price target by 237.5% from $8 to $27.
Sutro Biopharma reported its FY 2025 earnings.
Verdejo expressed optimism in the context of the print, noting that STRO-004 data is expected to be available in mid-2026.
Assuming robust data for STRO-004, the analyst predicted stock price appreciation from current levels.
According to Verdejo, STRO-004 has shown "early signs of differentiation" on ocular and skin toxicity in its pre-clinical profile, indicating that the treatment has a favorable efficacy and safety profile.
Earnings Report
For FY 2025, Sutro Biopharma reported:
- Loss per share of $22.49, compared to FY 2024’s loss of $29.40.
- Revenue of $102.5M, UP 65.3% Y/Y.
Management did not provide EPS and revenue guidance in its press release.
CEO Jane Chung commented: “2026 is poised to be a pivotal year, propelled by disciplined clinical execution and initial data that we believe will showcase the vast potential of our proprietary ADC platform.
“We recently completed dosing the third cohort in the Phase 1 trial of STRO-004, our potential best-in-class Tissue Factor ADC, and look forward to reporting initial data mid-year.
“In parallel, we are advancing STRO-006, our ITGB6 ADC, and accelerating STRO-227, our wholly owned dual-payload program targeting PTK7, toward IND submission this year.
“In addition, patient dosing has commenced under our collaboration with Astellas Pharma for our first partnered dual-payload iADC, marking the first dual-payload program from Sutro’s platform to enter the clinic.
“Supported by our recent financing, continued financial stewardship, and sharpened strategic focus, we believe we are well-positioned to execute across all our programs and deliver differentiated ADCs with best-in-class potential that could redefine standards of care in oncology.”
Reni Benjamin, a top 23% analyst from Citizens upgrades STRO to a buy rating and announces their STRO price target of $23.00, on Jan 20, 2026.
You can dig deeper into what analysts are projecting on the Sutro Biopharma stock forecast page.
Metrics for Advanced STRO Traders
How are STRO Revenues/Earnings doing?
Last year, STRO revenue was $99.61M. In the past five year, STRO's revenue has grown by 14.67% per year. This was slower than the Biotechnology industry average of 30%.
You can research STRO's earnings and revenue performance here.
Latest Insiders Trades at STRO
In the past year, insiders at STRO have bought more shares than they have sold.
Jane Chung, Chief Executive Officer of STRO, was the latest STRO insider to sell. They sold $6,009.42 worth of STRO stock on Mar 4, 2026.
Research more about who owns STRO shares here.
Can I rely on STRO as an income stream?
No, Sutro Biopharma doesn't provide an income stream by paying out dividends.
STRO Social Trading Data
One of the major reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to learn what other community members have to say.
Step 5: Execute your STRO buy order
You have two main options:
- Market order: A market order is an order to buy or sell a stock at the best possible price.
Market orders are generally fine for most investors. - Limit order: A limit order lets you buy or sell a stock at a specific price (or better).
If you want to make sure you're buying or selling at a particular dollar amount, place a limit order.
Click the Open button and eToro will place the order.
If you want additional info about buying stocks on eToro, watch the how to video below:
Step 6: Keep tabs on your STRO position
Now that you own some shares in STRO, you'll want to keep up with your new investment.
Make a watchlist to track the most important metrics related to your STRO stock.
STRO Feed
How to Buy Stock in Sutro Biopharma
To summarize, here are the 6 steps to buy stock in Sutro Biopharma:
- Figure out where to buy Sutro Biopharma stock
- Create your brokerage account
- Put funds into your investment account
- Analyze Sutro Biopharma stock
- Execute your STRO buy order
- Keep tabs on your STRO position
If you are looking for a brokerage, eToro is our favorite venue.
Get Started with eToro TodayIf you would like to get updates on your investment in Sutro Biopharma, hit the button below to create your watchlist.
More Articles You May Find Useful
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.